Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 6/20 | 0.43 |
| ▸ | FNTB | P49356 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911697 | 0.82 | AR (0.67) | ARMAPTTDP1TSHRSMN1; SMN2 | |
| SCHEMBL4919130 | 0.79 | AR (0.69) | ARFNTAFNTBKDM4EALDH1A1 | |
| SCHEMBL4920907 | 0.79 | AR (0.62) | ARMAPTTDP1TSHRSMN1; SMN2 | |
| SCHEMBL6468889 | 0.77 | AR (0.86) | ARTSHRKDM4EALDH1A1 | |
| SCHEMBL20944310 | 0.76 | TSHR (0.46) | MAPTTDP1TSHRSMN1; SMN2MAPK1 | |
| SCHEMBL4915699 | 0.75 | AR (0.58) | ARMAPTTDP1TSHRSMN1; SMN2 | |
| SCHEMBL4919894 | 0.75 | AR (0.58) | ARMAPTTDP1TSHRSMN1; SMN2 | |
| SCHEMBL4919103 | 0.75 | AR (0.56) | ARMAPTTDP1TSHRSMN1; SMN2 | |
| SCHEMBL5359879 | 0.75 | AR (0.52) | ARMAPTTDP1TSHRSMN1; SMN2 | |
| SCHEMBL6464447 | 0.75 | AR (0.53) | ARMAPTTDP1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176906-A1 | Substituted Pyrrole Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1824841-A1 | SUBSTITUTED PYRROLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006064944-A1 | SUBSTITUTED PYRROLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176906-A1 | Substituted Pyrrole Derivative | AR, NR5A1, MC2R | AR 1/4885MAPT 4670/4885TDP1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.